FDA Approves Epysqli (eculizumab-sbja) for PNH, aHUS, and gMG
FDA approves new drug Epysqli for three rare blood and nerve conditions.
The FDA approved Epysqli (eculizumab-sbja) for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and gen…
The FDA approved Epysqli (eculizumab-sbja) for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myas…
Low-dose IVIG shows similar efficacy to standard-dose IVIG in adults with AChR-positive generalized myasthenia gravis
Low-Dose IVIG Works as Well as High-Dose for MG
This prospective single-center cohort study evaluated low-dose versus standard-dose intravenous immunoglobulin (IVIG) in 34 adults with AChR…
A much smaller dose of IVIG may relieve severe muscle weakness in myasthenia gravis just as well as the standard high dose—cutting treatment…
Efgartigimod improved MG-ADL and QMG scores in 81 Chinese patients with generalized myasthenia gravis
Many Myasthenia Gravis Patients Need Just One Treatment Cycle
This single-center, retrospective analysis evaluated efgartigimod in 81 Chinese patients with generalized myasthenia gravis.
Most patients with myasthenia gravis controlled symptoms after a single treatment cycle, with fewer infusions possible for some.
Efgartigimod shows homogeneous efficacy across sexes in AChR-Ab+ generalized myasthenia gravis
New Hope for All Myasthenia Gravis Patients
This post hoc, sex-specific subgroup analysis of the ADAPT Phase 3 RCT evaluated efgartigimod in 86 females and 43 males with AChR-Ab+ gener…
A new treatment for myasthenia gravis works equally well for women and men, offering the same relief from severe muscle weakness regardless …
Complement inhibitors and FcRn blockers improve outcomes in AChR-Ab+ generalized myasthenia gravis
New Drugs Double Your Chance of Getting Better
A meta-analysis of 739 adults in RCTs and 588 in OLEs with acetylcholine receptor antibody-positive generalized myasthenia gravis found that…
New drugs for generalized myasthenia gravis double the odds of meaningful improvement while reducing the need for rescue therapy and severe …
CD19/BCMA CAR-T cells show early signal in six patients with refractory generalized myasthenia gravis
A One-Time Treatment Lets Patients with Severe Muscle Disease Stop Their Steroids
A Phase 1 study of 6 patients with refractory generalized myasthenia gravis found autologous CD19/BCMA CAR-T cells without prior lymphodeple…
A one-time infusion of engineered immune cells allowed patients with a debilitating muscle-weakening disease to stop steroids and live sympt…
Research across Myasthenia Gravis
Related studies from across the Myasthenia Gravis family.
Rare overlap of myasthenia gravis and Kennedy's disease identified in case report
Rare Overlap Syndrome Linked to Myasthenia Gravis and Kennedy's Disease
This case report and literature review describes a patient with acetylcholine receptor antibody-positive myasthenia gravis overlapping with …
A rare overlap between Myasthenia Gravis and Kennedy's disease was identified in a patient, helping doctors better recognize this complex co…
Meta-analysis of efgartigimod for myasthenia gravis reports efficacy and safety outcomes
New analysis shows intravenous efgartigimod helps many myasthenia gravis patients feel better and reduces symptoms quickly
This meta-analysis of 1594 patients with myasthenia gravis synthesized outcomes for intravenous efgartigimod. The authors report high rates …
A large review of data found that a new medicine called efgartigimod helps most patients with myasthenia gravis feel better. About eight out…
Pilot study explores ketogenic diet effects on symptoms in adults with generalized myasthenia gravis
Ketogenic diet may improve daily function in myasthenia gravis
This randomized, controlled, open-label pilot study examined whether a ketogenic diet improves functional status and quality of life in adul…
A small pilot trial hints that a keto diet could ease daily struggles for people with myasthenia gravis, but larger studies are needed.
Case report and literature review of thymoma associated with stiff person syndrome and myasthenia gravis
A Rare Muscle Stiffness Link to Thymoma Tumor Explained
This case report and literature review examines the association between thymoma and autoimmune syndromes including stiff person syndrome and…
A rare mix of muscle stiffness and weakness was traced to a thymoma tumor, with new genetic clues pointing to a shared immune cause.
Narrative review links myasthenia gravis and autoimmune encephalitis risk
MG and Brain Inflammation Linked in New Review
This narrative review examines the association between myasthenia gravis and autoimmune encephalitis.
This review reveals that myasthenia gravis is often linked to brain inflammation — and that may change how doctors treat tough cases.
Pyridostigmine improves symptoms and reduces costs in adults with AChR MG in a crossover trial
The Pill Millions Take Daily Finally Gets Proof It Works
A randomized, double-blind, placebo-controlled crossover trial in 19 adults with anti-acetylcholine receptor-positive myasthenia gravis (ACh…
After decades of widespread use, a medication that helps people with myasthenia gravis regain muscle control now has its first rigorous clin…
Autoantibodies neutralizing type I interferons linked to severe COVID-19 pneumonia in myasthenia gravis patients
A Hidden Immune Flaw Makes COVID Far More Dangerous for Some Patients
An international cohort study of 85 unvaccinated, untreated SARS-CoV-2-infected MG patients found that those with autoantibodies neutralizin…
Doctors have discovered why some people with a common nerve disease face a terrifying risk from COVID-19, pointing to a simple way to keep t…
Questions about generalized myasthenia gravis
Which specific antibodies must be present for Epysqli approval in myasthenia gravis?
Epysqli (eculizumab-sbja) is FDA-approved for generalized myasthenia gravis only in adult patients who test positive for anti-acetylcholine receptor (AChR) antibodies.
Full answer →Do complement inhibitors and FcRn blockers help patients with myasthenia gravis?
Yes, both complement inhibitors and FcRn blockers significantly improve symptoms and quality of life in AChR antibody-positive generalized myasthenia gravis, with a meta-analysis showing more than doubled odds of clinically meaningful improvement.
Full answer →Did efgartigimod improve daily living scores for Chinese patients with myasthenia gravis?
Yes, efgartigimod significantly improved MG-ADL scores in Chinese patients with generalized myasthenia gravis, with 80-97% achieving clinically meaningful improvement.
Full answer →Can Epysqli be used to treat generalized myasthenia gravis?
Yes, Epysqli (eculizumab-sbja) is FDA-approved for treating generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive.
Full answer →